kinesin family member 18B pseudogene 1Genealiases: []
Q-omics provides the consensus-scored KIF18BP1 profile across patient tissues and cancer cell-line models. KIF18BP1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KIF18BP1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KIF18BP1 RNA expression shows 6,532 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where KIF18BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF18BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF18BP1 survival associations across molecular data types. KIF18BP1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF18BP1 RNA expression–survival associations across cancer types. High KIF18BP1 expression shows unfavorable associations in UVM, THYM, TGCT, DLBC, LIHC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for KIF18BP1 RNA expression.
This table summarizes KIF18BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIF18BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF18BP1 shows lower tumor expression in KIRC, KIRP, KICH, BRCA and PRAD and higher tumor expression in HNSC. The KIRC box plot shows higher KIF18BP1 RNA expression in normal versus tumor tissue (log2 FC = −1.016, t-test p < 0.001).
This table shows molecular features associated with KIF18BP1 in patient tissues and cancer cell lines. In patient samples, KIF18BP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
